Effects of biologic antirheumatic treatments on bone metabolism in rheumatoid arthritis and ankylosing spondylitis;Wpływ leczenia biologicznego na metabolizm kostny chorych na reumatoidalne zapalenie stawów i zesztywniajace zapalenie stawów kregosłupa

Endokrynologia Polska

Volumn 60, Issue 2, 2009, Pages 115-121

  Głuszko, Piotr ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Ankylosing spondylitis; Inflammation induced bone loss; Rheumatoid arthritis; Targeted treatments

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIRHEUMATIC AGENT; ATLIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CYTOKINE; DENOSUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; ETIDRONIC ACID; GAMMA INTERFERON; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; ZOLEDRONIC ACID;

ANKYLOSING SPONDYLITIS; BONE DESTRUCTION; BONE EROSION; BONE MASS; BONE METABOLISM; BONE TURNOVER; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; FRAGILITY FRACTURE; HUMAN; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RHEUMATOID ARTHRITIS;

EID: 65749097416     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Głuszko P. Zapobieganie zlamaniom kości w chorobach reumatycznych. Standardy Medyczne 2007; 4:151-158.
2. Rell-Bakalarska M. Choroby reurnatyczne a osteoporoza. W: Lorenc RS, Olszyński WP (red.). Osteoporoza. Poradnik dla lekarzy. Biuro Gamma, Warszawa 2006: 80-83.
3. Klareskog L, Catrina IA, Paget S. Rheumatoid arthritis. Lancet 2009; 373: 659-672.
4. Maksymowych WP. What do biomarkers tell us about the pathogenesis of ankylosing spondylitis? Arthritis Res Ther 2009; 11: 101.
5. Inaba M. Secondary osteoporosis: thyreotoxicosis, rheumatoid arthritis and diabetes mellitus. J Bone Mineral Metab 2004; 22: 287-292.
6. Haugeberg G, Ørstavik RE, Kvien TK Effects of rheumatoid arthritis on bone. Curr Opin Rheumatol 2003; 4: 469-475.
7. Forsblad d'Elia H, Larsen A, Waltbrand E i wsp. Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis. Ann Rheum Dis 2003; 62: 617-623.
8. Døhn UM, Ejbjerg BJ, Court-Payen M i wsp. Do bone erosions, detected by magnetic resonance imaging and ultrasonography, represent true erosive changes? A comparison with computer tomography in rheumatoid arthritis metacarpophalangeal joints. Ann Rheum Dis 2005; 54 (supl. III): 84.
9. Scheinecker C, Smolen JS, Weyand CM. Essentials of the pathogenesis of rheumatoid arthritis. CMG, London 2008.
10. Stolina M, Kosteniuk PJ, Dougall WC i wsp. RANKL inhibition: from mice to men (and women). Adv Exp Med Biol 2007; 602: 143-150.
11. Pettit AR, Walsh NC, Manning C i wsp. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology 2006; 45: 1068-1076.
12. Kim HR, Kim HY, Lee SH. Elevated serum levels of soluble receptor activator of nuclear factor-kB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). Rheumatology 2006; 45: 1197-1200.
13. Saidenberg-Kermanach N, Corrado A, Lemeiter D. TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanism in collagen-induced arthritis. Bone 2004; 35: 1200-1207.
14. Cohen SB, Dore RK, Lane NE i wsp. Denosumab treatment effects on structural damage, bone mineral density and bone tumower in rheumatoid arthritis: a twelve month, multicenter, randomised, double blind, placebo controled, phase II trial. Arthritis Rheum 2008; 58: 1299-1309.
15. Geusens PP, Landewe RB, Garnero P i wsp. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 2006; 54: 1772-1777.
16. Leventis P, Patel S. Clinical aspects of vitamin D in the management of rheumatoid arthritis. Rheumatology 2008; 47:1617-1621.
17. Madsen OR, Sorensen OH, Egsmose C. Bone quality and bone mass as assesed by quantitative ultrasound and dual energy x-ray absorptiometry in women with rheumatoid arthritis: relationship with quadriceps strenth. Ann Rheum Dis 2002; 61: 325-329.
18. Kanis JA and WHO Scientific Group. Assessment of osteoporosis at the primary health care level. University of Sheffield 2007 UK.
19. Zimmermann-Gérska I. Reumatologia khniczna. Wydawnictwo Lekarskie PZWL, Warszawa 2008.
20. Shamji MF, Bafaguh M, Tsai E. The pathogenesis of ankylosing spondylitis. J Neurosurgery 2008; 24: E3.
21. Buckley CW. Spondyhtis deformans: its differential diagnosis and treatment by physical methods. Proc R Soc Med 1932; 105-110.
22. Mitra D, Elvins DM, Speder DJ i wsp. The prevalence of vertebral fractures in mild ankylosing spondylitis and their relationship to bone mineral density. Rheumatology 2000; 39: 85-89.
23. Lee YSL, Schlotzhauer T, Ott SM i wsp. Skeletal status of men with early and late ankylosing spondylitis. Am J Med 1997; 103: 233-241.
24. Toussirot E, Nguyen NU, Dumoulin G i wsp. Insulin-like growth factor- 1 and insulin-like growth factor binding protein-3 serum levels in ankylosing spondylitis. Rheumatology 1999; 38: 21-27.
25. Gillespie RE. Inflammation-induced bone loss: can it be prevented. Rheum Dis Chn North Am 2006; 32: 759-773.
26. Allali F, Breban M. Increase in BMD of patients with spondyloartropathy treated with anti-TNF. Ann Rheum Dis 2003; 63: 347.
27. Kelly C, Bartholomew P, Lapworth A i wsp. Peripheral bone density in patients with rheumatoid arthritis and factors which influence it. Eur J Intern Med 2002; 13: 423.
28. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticoid-induced osteoporosis: a meta-analysis. Osteoporosis Int 2002; 13: 777-787.
29. Dolan AL, Moniz C, Abraha H i wsp. Does active treatment of rheumatoid arthritis limit disease-associated bone loss? Rheumatology 2002; 41: 1047-1051.
30. Swensson B, Boonen A, Albertsson K i wsp. Low-dose prednisolone in addition to the initial disease-modifying antirlieurnatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two year randomised trial. Arthritis Rheum 2005; 52: 3360-3370.
31. Seriolo B, Paolino S, Sulli A i wsp. Are there any positive effects of TNF- -alpha blockers on bone metabolism. Reumatismo 2006; 58: 199-205.
32. Keystone E, Fleischmann R, Emery P i wsp. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007; 56: 3896-3908.
33. Genant HK, Peterfy CG, Westhowens R i wsp. Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis 2008; 67:1084-1089.
34. Cummings SR, McClung MR, Christiansen C i wsp. A phase III study of the effects of denosumab on vertebral, nonvertebral, and hip fracture in women with osteoporosis: Results from the FREEDOM trial. 30 ASBMR 2008 Abstract Book: 80, 1286.
35. Cohen SB, Dore RY, Lane NE i wsp. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomised, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008; 58: 1299-1309.
36. Breuil V, Euller-Ziegler L. Bisphosphonate therapy in rheumatoid arthritis. Joint Bone Spine 2006; 73: 349-354.
37. Jarret SJ, Conaghan PG, Sloan VS i wsp. Preliminary evidence for a strustural benefit of the new bisphosphonate zolendronic acid in early rheumatoid arthritis. Arthritis Rheum 2006; 54: 1410-1414.
38. Sidiropoulos PI, Hatemi G, Song LH i wsp. Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E initiative in rheumatology involving a broad panel of experts and practising rheumatologists. Rheumatology 2008; 47: 355-361.
39. Maksymowych WP, Rahman P, Shojania K i wsp. Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis. J Rheumatol 2008; 35: 2030-2037.
40. Demis E, Roux C, Breban M iwsp. Infliximab in spondyloarthropathy- influence on bone density. Clin Exp Rheumatol 2002; 20: (supl. 28): S185-S186.
41. Visvanathan S, Wagner C, Marini JC i wsp. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis. J Rheumatol 2008; 35: 2030-2037.
42. Maksymowch WP, Jhangri GS, Fitzgerald AA i wsp. A six month randomized, controlled, double-blind, dose response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002;46:766-773.
43. Głuszko P, Korkosz M. Evidence for antiinflammatory properties of clodronate in patients with ankylosing spondylitis. Ann Rheum Dis 1999; (supl. 1): 122.
44. Smolen JS, Beaulieu A, Rubbert-Roth A i wsp. Effect of interleukin-6 receptor 3 inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double blind, placebo-controlled, randomised trial. Lancet 2008; 371: 987-997.